ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Biotechnology

China's Sinopharm doubles output capacity for 2020 vaccine launch

Drugmaker's two plants can produce 200m doses as candidate moves through trials

Eighteen potential vaccines are in clinical trials, with seven being developed by Chinese pharmaceutical companies.   © Reuters

DALIAN, China -- Chinese drugmaker Sinopharm has completed construction of a plant in Wuhan for mass production of a coronavirus vaccine candidate now under development, doubling its capacity to more than 200 million doses a year 

The state-backed company, known formally as China National Pharmaceutical Group, will be able to make 100 million doses a year at the site. The investment amount has not been disclosed. After the groundbreaking in March, construction took place quickly with support from the local government.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more